Document is current
Any future updates will be listed below
-
Authors
Chapagai, Danda https://orcid.org/0000-0003-3317-0658
Strebhardt, Klaus https://orcid.org/0000-0003-2173-9763
Wyatt, Michael D. https://orcid.org/0000-0003-1815-9565
McInnes, Campbell https://orcid.org/0000-0002-5592-9082
- License Information
-
More Information
Article History
Received: 25 October 2024
Revised: 2 April 2025
Accepted: 9 April 2025
First Online: 16 May 2025
Competing interests
: In addition to his primary affiliation at the University of South Carolina, CM is President and CSO of PPI Pharmaceuticals, LLC, developing inhibitors as PLK1 as next generation cancer therapeutics. No other authors declare competing interests.
